Table A2.
Subgroup analyses of the prevalence of anxiety, depression, and insomnia.
| Groups | Subgroups | Anxiety | Depression | Insomnia |
|---|---|---|---|---|
| Number of studies | 27 | 24 | 9 | |
| Number of samples | 31 | 26 | 10 | |
| Number of prevalence | 62 | 54 | 21 | |
| Number of participants | 14,847 | 12,688 | 4144 | |
| Aggregated | 37%, 95% CI: 31–44% | 45%, 95% CI: 38–53% | 28%, 95% CI: 18–40% | |
| Population | Frontline HCWs | 51%, 95% CI: 31–70% | 55%, 95% CI: 32–76% | 30%, 95% CI: 2–71% |
| General HCWs | 35%, 95% CI: 23–48% | 43%, 95% CI: 39–58% | 28%, 95% CI: 13–45% | |
| General population | 37%, 95% CI: 28–46% | 42%, 95% CI: 31–55% | 27%, 95% CI: 9–50% | |
| Medical student | 31%, 95% CI: 13–54% | 48%, 95% CI: 27–69% | 32%, 95% CI: 39–64% | |
| Severity | Above mild | 62%, 95% CI: 56–69% | 65%, 95% CI: 56–75% | 52%, 95% CI: 39–64% |
| Above moderate | 33%, 95% CI: 26–41% | 41%, 95% CI: 33–50% | 19%, 95% CI: 11–29% | |
| Severe | 14%, 95% CI: 07–31% | 20%, 95% CI: 13–29% | 4%, 95% CI: 3–6% | |
| Overall | 18%, 95% CI: 07–31% | 14%, 95% CI: 10–20% | NA | |
| Region | Sub-Sahara | 31%, 95% CI: 23–40% | 30%, 95% CI:22–40% | 24%, 95% CI:11–40% |
| North Africa | 44%, 95% CI: 34–53% | 55%, 95% CI: 46–65% | 31%, 95% CI: 18–47% | |
| Instruments | GAD-7/PHQ-9 | 34%, 95% CI: 25–43% | 43%, 95% CI: 33–54% | NA |
| DASS-22 | 44%, 95% CI: 31–57% | 43%, 95% CI: 29–59% | ||
Note: CI = Confidence Interval.